Chelsie Monroe, NP, on the Game-Changing Role of Muscarinic Modulators in Schizophrenia

In this insightful interview, Chelsie Monroe, a nurse practitioner, breaks down the exciting potential of Cobenfy, the first new class of schizophrenia medication in 70 years. Unlike traditional antipsychotics, which target post-synaptic D2 receptors, Cobenfy works presynaptically through cholinergic pathways, offering a fresh approach to managing positive, negative, and cognitive symptoms.

Monroe discusses how this novel mechanism of action could lead to cognitive improvements, key dosing considerations, and what clinicians should keep in mind when prescribing. Tune in to learn more about how Cobenfy is paving the way for future treatments and improving outcomes for patients with schizophrenia.

Read more: https://www.hcplive.com/view/consider...

Key Highlights:
00:007: Muscarinic Modulator’s Impact on Schizophrenia Landscape
02:16: Considerations Clinicians Should Keep in Mind When Incorporating These Modulators into Care
04:03: Challenges with Muscarinic Modulators
06:51: Muscarinic Modulators in Current Research

#MuscarinicModulators #Cobenfy #KarXT #xanomelinetrospium #schizophrenia